Correlation Between PaxMedica, Common and Unicycive Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both PaxMedica, Common and Unicycive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining PaxMedica, Common and Unicycive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between PaxMedica, Common Stock and Unicycive Therapeutics, you can compare the effects of market volatilities on PaxMedica, Common and Unicycive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in PaxMedica, Common with a short position of Unicycive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of PaxMedica, Common and Unicycive Therapeutics.

Diversification Opportunities for PaxMedica, Common and Unicycive Therapeutics

-0.77
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between PaxMedica, and Unicycive is -0.77. Overlapping area represents the amount of risk that can be diversified away by holding PaxMedica, Common Stock and Unicycive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unicycive Therapeutics and PaxMedica, Common is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on PaxMedica, Common Stock are associated (or correlated) with Unicycive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unicycive Therapeutics has no effect on the direction of PaxMedica, Common i.e., PaxMedica, Common and Unicycive Therapeutics go up and down completely randomly.

Pair Corralation between PaxMedica, Common and Unicycive Therapeutics

Given the investment horizon of 90 days PaxMedica, Common Stock is expected to under-perform the Unicycive Therapeutics. But the pink sheet apears to be less risky and, when comparing its historical volatility, PaxMedica, Common Stock is 1.25 times less risky than Unicycive Therapeutics. The pink sheet trades about -0.02 of its potential returns per unit of risk. The Unicycive Therapeutics is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  70.00  in Unicycive Therapeutics on September 7, 2024 and sell it today you would lose (1.00) from holding Unicycive Therapeutics or give up 1.43% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy30.1%
ValuesDaily Returns

PaxMedica, Common Stock  vs.  Unicycive Therapeutics

 Performance 
       Timeline  
PaxMedica, Common Stock 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days PaxMedica, Common Stock has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, PaxMedica, Common is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders.
Unicycive Therapeutics 

Risk-Adjusted Performance

15 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

PaxMedica, Common and Unicycive Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with PaxMedica, Common and Unicycive Therapeutics

The main advantage of trading using opposite PaxMedica, Common and Unicycive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if PaxMedica, Common position performs unexpectedly, Unicycive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unicycive Therapeutics will offset losses from the drop in Unicycive Therapeutics' long position.
The idea behind PaxMedica, Common Stock and Unicycive Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Complementary Tools

Global Correlations
Find global opportunities by holding instruments from different markets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities